Sponsor: 
Sanofi-Aventis Australia
Administration route: 
Subcutaneous injection
Vaccine group: 
Japanese encephalitis vaccines

Registered for use in people aged ≥9 months.

Live attenuated Japanese encephalitis vaccine

Lyophilised powder in a monodose vial with separate diluent.

Each 0.5 mL reconstituted dose contains:

  • 4.0–5.8 log plaque-forming units of live attenuated recombinant Japanese encephalitis virus
  • mannitol
  • lactose
  • glutamic acid
  • potassium hydroxide
  • histidine
  • human serum albumin

No adjuvants or antibiotics are added.

For full details, refer to the product information and consumer medicine information sheets for Imojev vaccine available on the TGA website.

Page history

Last updated: 
4 June 2018
Last reviewed: 
4 June 2018